CLINICAL STUDY PROTOCOL  
 
 
An Analysis  of the Efficacy  of a Pre- 
Emptive Multimodal Pain Regimen in 
Reducing Acute Post -Operative Pain and 
Narcotic Pain Medication Requirements 
in Spine Surgery  
385 First Street, Apt -3S 
MINEOLA,  NY, 11501,  United  States  
 
Protocol  Version  
May 12, 2020  
version  2 
 
 
 
 
 
 
 
 
 
 
Confidentiality  Statement:  Study ID: [REMOVED]  
Study Number: 20 -00734 
PI: Muhammad Tariq,  MD 
Protocol Number  May 12, 2020 - version 2 
2  
 Study  Personnel  
Investigator  Muhammad  Tariq  
NYU  Winthrop  Hospital 
United States  
Tel: 6023631134  
Email:  tariqm03@nyulangone.org  
Protocol Number  May 12, 2020 - version 2 
3  
 Synopsis  
 
 
Primary  Objective  
 
Aim 1: Determine  pain control  post-operatively after  elective spine  surgery  
Secondary  Objectives  
 
 
Aim 2:  Determine  patient  variables  significantly  associated  with post-operative  pain 
control  
 
 
Aim 3:  Determine  operative  variables  significantly  associated  with post-operative  pain 
control  
 
 
Aim 4:  Determine  long term  outcomes  and complication  rates  after  pre-emptive  MMA 
regimen implementation  
Study  Duration  
 
Expected  Duration:  2020  to 2022  
Study  Design  
 
Prospective  Cohort  Study  
Study  Population  
 
Adult  patients  undergoing  elective  spine  surgery  at NYU  Winthrop  Hospital  
 
Protocol Number  May 12, 2020 - version 2 
4  
  
Number  of Participants  
 
At a significance  level  of 5%, in order  to achieve  80%  power  for detecting  a 1 point  mean 
difference  in VAS  pain scores [1], we would  need  a sample  of 31 patients  to assess  the 
primary outcome. Adjusting by approximately 5% to account for patients that are found 
ineligible retrospectively, the total sample size required is 33 patients for the primary 
outcome.  
Furthermore,  additional  analyses  to fulfill  Aims  2-4 would  require  a larger  sample  size and 
would constitute separate studies based on final sample size achieved  
 
[1] Using  the reported  control  group  VAS  scores  by Garcia  et al. of 8.4 and standard 
deviation of 2  
Number  of Study  Sites  
 
The study  will be conducted  out of NYU  Winthrop  hospital  as well as in the outpatient 
office settings.  
Primary  Outcome  Variables  
 
Aim 1: Determine  pain control  post-operatively after  elective spine  surgery  
 
 
Measure  acute  pain using  the VAS  pain scale  in PACU  
 
Measure  opioid  sparing  and rescue  time as determined  by the time interval  from 
patient extubation to time when pain medication is first demanded in PACU  
 
Determine  secondary  outcomes:  length  of stay in PACU,  opioid  dose,  drain  output, 
transfusion rates, and hospital length of stay.  
Secondary  and Exploratory  Outcome  Variables  
 
Aim 2: Determine  patient  variables  significantly  associated  with above  outcomes  
 
 
The following variables will be considered: age, gender, race, comorbidities, pain 
medication  use prior  to surgery  (including  dose  and number  of years  used),  history  of 
Protocol Number  May 12, 2020 - version 2 
5  
  
seeing  a pain management  physician,  history  of psychological  illnesses,  demographic 
history, use of ambulatory aids and activity level at baseline  
 
 
Aim 3: Determine  operative  variables  significantly  associated  with above  outcomes  
 
 
The following  variables  will be considered:  primary  vs revision  surgery,  surgical  site, 
number of spinal levels, length of surgery, use of intr a-operative dexamethasone, 
blood loss, ASA score  
 
 
Aim 4:  Determine  long term  outcomes  and complication  rates  after  pre-emptive  MMA 
regimen implementation  
 
Determine  patient  reported  VAS  pain  scores  at 3 , 6, and 12 months  post-operatively  
 
Determine long term pain medication use at 3 , 6, and 12 months post -operatively 
Determine  rate of surgical  complications  including  surgical  site infection,  readmission, 
pseudoarthrosis/lack of fusion rates, hardware complication, revision surgery, 
neurolo gical deficit  
Visit  Schedule  Table  (Optional)  
Study  Flow  Chart  (optional)  
Protocol Number  May 12, 2020 - version 2 
6  
 Explanation  Abbreviation  Abbreviations  
 
Protocol Number  May 12, 2020 - version 2 
7  
 Explanation  Glossary  Glossary  of Terms  
 
Protocol Number  May 12, 2020 - version 2 
8  
 Table  Of Contents  
Synopsis  ................................ ................................ ................................ ................................ ..... 3 
An Analysis  of the Efficacy  of a Pre-Emptive  Multimodal  Pain  Regimen  in Reducing  
Acute  Post -Operative  Pain  and Narcotic  Pain  Medication  Requirements  in Spine  Surge  ry3 
Primary  Objective  ................................ ................................ ................................ ................................  3 
Secondary  Objectives  ................................ ................................ ................................ ........................  3 
Study  Duration  ................................ ................................ ................................ ................................ .... 3 
Study  Design ................................ ................................ ................................ ................................ ....... 3 
Study  Population  ................................ ................................ ................................ ................................  3 
Number  of Participants ................................ ................................ ................................ ......................  3 
Number  of Study  Sites  ................................ ................................ ................................ ......................  3 
Primary  Outcome  Variables  ................................ ................................ ................................ .............  3 
Secondary  and Exploratory  Outcome  Variables  ................................ ................................ ..........  3 
Visit Schedule  Table  (Optional)  ................................ ................................ ................................ ....... 3 
Abbreviations ................................ ................................ ................................ ................................ ....... 6 
Glossary  of Terms  ................................ ................................ ................................ ..............................  7 
1 - Introduction  ................................ ................................ ................................ ......................  11 
1.1 Introductory  Statement  ................................ ................................ ................................ ...........  11 
2 - Background  ................................ ................................ ................................ ......................  12 
2.1.1  Preclinical  Experience  ................................ ................................ ................................ ...........  12 
2.1.2  Clinical Experience  ................................ ................................ ................................ ..........................  12 
2.2 Background/prevalence  of research  topic  ................................ ................................ ..........  14 
3 - Rationale/Significance  ................................ ................................ ................................ . 15 
3.1 Problem  Statement  ................................ ................................ ................................ ...................  15 
3.2 Purpose  of Study/Potential  Impact  ................................ ................................ .......................  15 
3.3.1  Potential  Risks ................................ ................................ ................................ ................................  15 
3.3.2  Potential  Benefits  ................................ ................................ ................................ ........................... 16 
4 - Study  Objectives  ................................ ................................ ................................ ...........  17 
4.1 Hypothesis  ................................ ................................ ................................ ................................ . 17 
4.2 Primary  Objective  ................................ ................................ ................................ ......................  17 
4.3 Secondary  Objectives  ................................ ................................ ................................ ..............  17 
5 - Study  Design  ................................ ................................ ................................ ..................  18 
5.1 General  Design  Description ................................ ................................ ................................ .... 18 
5.1.1  Study  Date  Range  and Duration ................................ ................................ ................................ . 18 
5.1.2  Number  of Study  Sites  ................................ ................................ ................................ .................. 18 
5.2 Outcome  Variables  ................................ ................................ ................................ ..................  18 
5.2.1  Primary  Outcome  Variables  ................................ ................................ ................................ .......... 19 
5.2.2  Secondary  and Exploratory  Outcome  Variables  ................................ .............................  19 
5.3 Study  Population  ................................ ................................ ................................ ......................  19 
5.3.1  Number  of Participants  ................................ ................................ ................................ ................... 19 
5.3.2  Eligibility  Criteria/Vulnerable  Populations  ................................ ................................ ................. 19 
6 - Methods  ................................ ................................ ................................ ............................  21 
6.1 Treatment  - Drug  ................................ ................................ ................................ .....................  21 
6.1.1  Identity  of Investigational  Product/New  Drug  ................................ ................................ .........  21 
Protocol Number  May 12, 2020 - version 2 
9  
 6.1.2  Dosage,  Admin,  Schedule  ................................ ................................ ................................ ............ 21 
6.1.3  Method  of Assignment/Randomization  ................................ ................................ ...............  21 
6.1.4  Blinding  and Procedures  for Unblinding  ................................ ................................ ...........  21 
6.1.5  Packaging/Labelling  ................................ ................................ ................................ ....................... 21 
6.1.6  Storage  Conditions  ................................ ................................ ................................ ......................... 21 
6.1.7  Concomitant  therapy  ................................ ................................ ................................ ..................... 21 
6.1.8  Restrictions  ................................ ................................ ................................ ................................ ......22 
6.2 Assessments  ................................ ................................ ................................ ..............................  22 
6.2.1  Efficacy  ................................ ................................ ................................ ................................ ............. 22 
6.2.2  Safety/Pregnancy -related  policy  ................................ ................................ ................................ .23 
6.2.2.1  Adverse  Events  Definition  and Reporting  ................................ ................................ .............. 23 
6.2.3  Pharmacokinetics  ................................ ................................ ................................ ..................  23 
6.2.4  Biomarkers  ................................ ................................ ................................ .............................  23 
6.3 Study  Procedures  ................................ ................................ ................................ .....................  23 
6.3.1  Study  Schedule ................................ ................................ ................................ ............................... 23 
6.3.2  Informed  Consent  ................................ ................................ ................................ .......................... 23 
6.3.3  Screening  ................................ ................................ ................................ ................................ .........24 
6.3.4  Recruitment,  Enrollment  and Retention  ................................ ................................ .........  24 
6.3.5  On Study  Visits  ................................ ................................ ................................ ............................... 24 
6.3.6  End of Study  and Follow -up ................................ ................................ ................................ .........24 
6.3.7  Removal  of subjects ................................ ................................ ................................ ....................... 24 
6.4 Statistical  Method ................................ ................................ ................................ ....................  24 
6.4.1  Statistical  Design  ................................ ................................ ................................ ........................... 25 
6.4.2  Sample  Size Considerations  ................................ ................................ ................................ .........25 
6.4.3  Planned  Analyses  ................................ ................................ ................................ ...................  25 
6.4.3.1  Primary  Analyses  ................................ ................................ ................................ ..............  25 
6.4.3.2  Secondary  Objectives  Analy ses ................................ ................................ .....................  25 
6.4.3.3  Safety/Pregnancy -related  policy  ................................ ................................ ....................  25 
6.4.3.4  Analysis  of Subject  Characteristics  ................................ ................................ .................  25 
6.4.3.5  Interim  Analysis ................................ ................................ ................................ .................  26 
6.4.3.6  Health  economic  evaluation  ................................ ................................ ............................  26 
6.4.3.7  Other  ................................ ................................ ................................ ................................ .... 26 
6.4.4  Subsets  and Covariates  ................................ ................................ ................................ ................ 26 
6.4.5  Handling  of Missing  Data  ................................ ................................ ................................ .............. 26 
7 - Trial  Administration  ................................ ................................ ................................ ..... 27 
7.1 Ethical Considerations:  Informed  Consent/Assent and  HIPAA  Authorizatio n ...............  27 
7.2 Institutional  Review  Board  (IRB)  Review  ................................ ................................ ............  27 
7.3 Subject  Confidentiality  ................................ ................................ ................................ ............  27 
7.4 Deviations/Unanticipated  Problems  ................................ ................................ ....................  27 
7.5 Data  Collection  ................................ ................................ ................................ .........................  27 
7.6 Data  Quality  Assurance  ................................ ................................ ................................ ..........  27 
7.7 Study  Records  ................................ ................................ ................................ ...........................  27 
7.8 Access  to Source  ................................ ................................ ................................ ......................  27 
7.9 Data  or Specimen  Storage/Security  ................................ ................................ .....................  28 
7.10  Retention  of Records  ................................ ................................ ................................ ............  28 
Protocol Number  May 12, 2020 - version 2 
10  
 7.11  Study  Monitoring  ................................ ................................ ................................ ....................  28 
7.12  Data  Safety  Monitoring  Plan  ................................ ................................ ...............................  28 
7.13  Study  Modification  ................................ ................................ ................................ .................  28 
7.14  Study  Discontinuation ................................ ................................ ................................ ............  28 
7.15  Study  Completion ................................ ................................ ................................ ...................  28 
7.16  Conflict  of Interest  Policy  ................................ ................................ ................................ ..... 28 
7.17  Funding  Source  ................................ ................................ ................................ ......................  28 
7.18  Publication  Plan ................................ ................................ ................................ ......................  29 
Appendices  ................................ ................................ ................................ ................................ ....... 30 
References  ................................ ................................ ................................ ................................ .........  31 
Protocol Number  May 12, 2020 - version 2 
11  
 1 - Introduction  
1.1 Introductory  Statement  
 
Pain following surgery of the spine is a c ommon complaint9. In addition, pain is the second 
leading cause of readmission2. Continued research for novel and improved methods for 
post-operative pain control is vital; especially given the recent rising healthcare urgency to 
limiting opioid use amidst  the opioid abuse crisis. Historically, post -operative pain control 
regimens have relied heavily on opioid medications provided at intervals in response to as 
needed  protocols3. However,  several  limitations  exist  to this model  of pain control  including 
poor pain control and a host of opioid induced adverse effects35. 
Recently significant interest has been brought to the utilization of multimodal analgesia 
(MMA)15. MMA takes advantage of the synergistic effect of multiple pain medications that 
act through  different  mechanisms  of actions  to target  pain more  effectively.  Several  studies 
have highlighted the efficacy of such regimens and have proven that these regimens are 
safe5,6,8,12,15,24,31,37. 
Furthermore, the pre -emptive administration of pain  medications has been believed to be 
more efficacious in controlling post -operative pain36. Pre -emptive control of pain is thought 
to mitigate  or halt central  nervous  system  sensitization  (which  includes  prolonged  changes) 
as a result of noxious stimuli su ch as surgery36. Therefore, we sought to evaluate the 
efficacy of a pre -emptive MMA pain regimen in controlling post -operative pain in a 
community hospital setting.  
Protocol Number  May 12, 2020 - version 2 
12  
 2 - Background  
2.1.1  Preclinical  Experience  
 
A wide  range  of pharmacological  options  are available  for the effective  amelioration  of post 
spine  surgery  pain.  Each  analgesic  choice  possesses  inherent  advantages  and 
disadvantages to its applicability15. 
Acetaminophen, one of the most commonly used non -opioid analgesic s utilized exerts its 
effects though cyclooxygenase (COX) inhibition. Multiple studies have demonstrated 
improved pain control and reduced opioid use with acetaminophen use in patients 
undergoing  orthopaedic  procedures29,33. As such  acetaminophen  remains  a cornerstone  in 
most multimodal pain regimens.  
Nonsteroidal anti -inflammatory (NSAID) medications are another commonly utilized 
analgesic choice. They exert their anti -inflammatory and analgesic effects via COX 
inhibition therefore b locking prostaglandin production. Although COX1 are ubiquitous 
throughout the body, COX2 enzymes are more specific to inflammatory tissues. Specific 
COX2  inhibitors  were  developed  in order  to minimize  adverse  effects  of COX1  inhibition  (ie 
gastric mucosa d amage and platelet dysfunction). However, there has been controversy 
over  the use of NSAIDs  in spine  surgery  given  concerns  for nonunion,  pseudoarthrosis,  and 
bleeding/hematoma  formation.  A number  of studies  have  shown  higher  nonunion  rates  in a 
dose  dependent  manner  with the use of NSAIDs19,39. Nevertheless,  recent  studies  highlight 
that COX2  inhibitors  as well as NSAIDs  used  in lower  doses  prove  to be efficacious  for pain 
control and may not carry the same adverse effects as previously thought10,11,2 1,27. 
Gabapentin  and pregabalin  are neuromodulatory  agents  commonly  used  for neuropathic 
pain. They work by inhibiting calcium gated channels on presynaptic axons thereby 
reducing neuronal excitability. The efficacy of these neuromodulatory agents in post- 
operative pain control and reduction of opioid consumption is well documented in spine 
surgery with multiple level I studies presenting positive outcomes7,20,34,38. 
Oxycodone is a standard opioid pain medication that is widely accepted as part of a p ain 
regimen  for post-operative  pain  control4. The medication  works  by decreasing  excitability  of 
neurons by binding to mu, kappa, and delta receptors thereby inhibiting adenylyl cyclase 
signaling pathway23. 
Limited literature exists on the efficacy of thes e commonly used analgesics as part of a 
multimodal regimen especially one given pre -operatively. Therefore we sought to 
investigate  the efficacy  of a MMA  regimen  administered  pre-operatively  in terms  of acute 
post-operative pain control and opioid pain med ication requirements.  
 
 
2.1.2  Clinical  Experience  
 
The use MMA  regimens  for controlling  post-operative  pain  continue  to gain acceptance  and 
popularity6,8,12,15. The idea of MMA relies on the synergistic action of multiple agents 
working  to inhibit  pain  through  distinct  mechanisms  along  the pain pathway.  MMA  prove  to 
Protocol Number  May 12, 2020 - version 2 
13  
 improve pain control, reduce opioid consumption, decrease adverse effects, and facilitate 
recovery and rehabilitation. Furthermore, the use of analgesic agents prior to the insult of 
pain may prove to have further value by preventing pain and controlling pain before its 
onset  thereby  reducing  sensitization.  Limited  studies  have  looked  at MMA  efficacy  in spine 
surgery and very limited literature exists on its efficacy if given  pre-emptively (ie pre - 
operatively)1,13,14,16,36. 
Garcia et al. report their findings of a preemptive MMA regimen with 22 patients 
undergoing lumbar laminectomy surgery8. In this randomized control trial (RCT), patients 
received either IV morphine only or MMA regimen consisting of 200 mg celecoxib pre -op 
and 100 mg post -op, 15 mg pregabalin pre -op, and 10 mg oxycodone extended -release 
given twice daily post -op. Medication s were administered every 12 hours with first dose 
given pre -op. All patients were allowed to receive IV morphine post -op on an as needed 
basis.  Pain  levels  were  assessed  using  the VAS  pain  scale  at 0, 4, 8, 12, 16, 24, and 48 
hours  post-op. IV morphine  requirements  were  recorded  6,12,  and 24 hours  post-op. They 
found  that compared  to the IV morphine  group,  the MMA  group  had lower  VAS  pain  scores 
at all time points, a 58% reduction in morphine consumption and earlier oral food intake. 
No difference in intra -operative blood loss was noted.  
 
Another  RCT  by Kim et al. looked  at preemptive  MMA  efficacy  in single  level  lumbar  fusion 
surgery  in 80 patients14. Regimen  consisted  of 500 mg acetaminophen,  200 mg celecoxib, 
75 mg of pregabalin,  and 10 mg extended  release  oxycodone  given  1 hour  before  surgery 
and then  twice  daily.  IV morphine  was used  in the control  group.  They  found  improved  VAS 
pain scores at all time points and lower Oswentry Disability Index scores at all time points 
except day 1 post-op. Of note they did not find a difference in acute complications or in 
fusion rates at 1 year. No difference in intra -operative blood loss was noted.  
Lee et al. looked at a retrospective observational study of 393 patients undergoing lumbar 
spinal fu sion from 17 hospitals sent a post -op questionnaire16. Only 79 of these patients 
were noted to have received preemptive analgesics; COX2 inhibitors with or without 
gabapentin/pregabalin.  363 patients  received  some  form  of MMA  post-operatively.  They  did 
not find significant differences in outcomes with the post -op MMA protocols assessed.  
However, preemptive pain regimen group reported significantly lower self -administered 
PCA  use post-op. Furthermore,  EQ-5D activity,  depression/anxiety,  and self-care  also 
improved significantly in the preemptive group at 2 weeks post -op. It is worth noting the 
retrospective  and observational  nature  are limitations  to the study  as well as possibility  of 
selection and recall bias.  
A recent  study  by Kien  et al. looked  at the preemptive  use of pregabalin  and celecoxib  in 60 
lumbar spine fusion surgery patients in a prospective cohort study13. The patients were 
randomized  to receive  either  the MMA  regimen  or placebo  2 hours  pre-op. The MMA 
consisted  of pregabalin  150 mg and celecoxib  200 mg. Post -op pain was managed  with a 
morphine  PCA.  They  noted  VAS  pain  scores  and morphine  consumption  to be significantly 
lower in the treatment group at 24 and 48 hours post -op. 
Finally, Mathiesen et al. and Rajpal et a l. are additional retrospective studies looking at 
primarly post -op MMA after spine lumbar fusion surgery in 85 and 200 patients 
respectively22,26. They  also note  improved  pain control  and lower  opioid  requirements  in the 
intervention groups.  
Protocol Number  May 12, 2020 - version 2 
14  
 Unfortunately,  the long  term  outcomes  including  fusion  rates  and complications  such  as 
pseudarthrosis were not found in our review to be reported by any of the studies.  
 
 
 
 
2.2 Background/prevalence  of research  topic  
Protocol Number  May 12, 2020 - version 2 
15  
 3 - Rationale/Significance  
3.1 Problem  Statement  
 
Increasing  demand  for elective  spine  surgery  accentuates  the importance  of improving 
outcomes  and lowering  costs.  One of the key challenges  in spine  surgery  remains  to be 
post-operative pain control. Pain leads to a number of adverse effects on physical, 
emotional, and social health as well as to short and long term outcomes32. 
 
 
3.2 Purpose  of Study/Potential  Impact  
 
Adequate  and effective  pain control  leads  to lower  risk of complications,  greater  patient 
satisfaction, and earlier mobility, rehab as well as recovery from surgery17,18,25,31. 
Traditionally pain control has focused on opioid pain medications utilized on an as pain 
occurs basis post -operatively3. However, recent advances in pain control  research have 
brought up a shift in paradigm to targeting pain earlier1,16,36. Pain leads to a cascade of 
neuronal activation as well as some changes that may be long term in the central nervous 
system36. Therefore blocking the pain pathway earlier prior to prevent is thought to prevent 
central sensitization to pain and prevent these long term changes in the central nervous 
system. Furthermore, this paradigm of targeting pain before it occurs is thought to lead to 
more  effective  pain control  as well as reduce the opioid  dependency  on post-operative  pain 
control1,16. 
Utilizing  multiple  agents  to control  pain is conjectured  to work  in a synergistic  manner, 
described  as multimodal  analgesia(MMA)37. This allows  not only a strategy  to target  pain 
more  effectively  through  numerous  distinct  pathways  but also allows  the use of lower  doses 
of each  individual  analgesic  therefore  mitigating  adverse  effects  of each  medication12,15,28. 
A growing  body  of evidence  supports  the utility  of MMA  in spine  surgery30. 
Therefore  significant  interest  exists  in optimizing  MMA  protocols  especially  prior  to the 
onset  of pain  for treating  patients  undergoing  spine  procedures12,15,16,37. 
 
 
3.3.1  Potential  Risks  
 
Potential  risks  include  any described  adverse  effects  of the analgesic  medications  as well as 
undescribed effects of these medications on surgery or outcomes. However, since these 
medications are routinely used and common practice their effectiveness and safety have 
been thoroughly described previously in the li terature. Furthermore, patients with health 
conditions that would put them at higher risk are excluded from the study. In addition, the 
medications to be used have been previously described to be safe in similar studies. For 
example, NSAIDs have been tradi tionally avoided due to risks on platelet function and 
operative  blood  loss.  However,  the use of celecoxib  which  has minimal  effect  on COX1 
associated  with platelet  function.  Celecoxib  has also been  described  in a number  of studies 
for pain control in spine surgery without any evidence of increased blood loss.  
Protocol Number  May 12, 2020 - version 2 
16  
  
 
 
 
3.3.2  Potential  Benefits  
 
Some of the strengths of this study include its novel nature to assess pre -op MMA in all 
areas  of spine,  prospective  nature,  relativ ely large  sample  size,  and the analysis  of multiple 
patient and treatment parameters in the context of pain control.  
Adequate  and effective  pain control  leads  to lower  risk of complications,  greater  patient 
satisfaction, and earlier mobility, rehab as well as recovery from surgery17,18,25,31. 
The long term implications are promising in terms of patient care and future post -op pain 
control after spine surgery. This study will significantly add to better controlling pain in the 
post-op period, improving o utcomes, and facilitating recovery after elective spine surgery.  
Protocol Number  May 12, 2020 - version 2 
17  
 4 - Study  Objectives  
4.1 Hypothesis  
 
Multimodal pain regimen (consisting of acetaminophen, celecoxib, gabapentin, and 
oxycodone) administered pre -operatively before elective spine surgery significantly 
decreases acute pain post -operatively as well as decreasing requirements of post -op 
opioids  for pain control  in PACU  as compared  to patients  undergoing  elective  spine  surgery 
without a pre -operative pain regimen.  
 
 
4.2 Primary  Objective  
 
Aim 1: Determine  pain control  post-operatively after  elective spine  surgery  
 
 
 
 
 
 
4.3 Secondary  Objectives  
 
 
Aim 2: Determine  patient  variables  significantly  associated  with post-operative  pain control  
 
 
Aim 3:  Determine  operative  variables  significantly  associated  with post-operative  pain 
control  
 
 
Aim 4:  Determine  long term  outcomes  and complication  rates  after  pre-emptive  MMA 
regimen implementation  
Protocol Number  May 12, 2020 - version 2 
18  
 5 - Study  Design  
5.1 General  Design  Description  
 
A prospective  cohort  study  with patients  undergoing  elective  spine  surgery  at NYU  winthrop 
will be recruited for participation based on described inclusion and exclusion criteria. A 
prospective study allows the implementation of the new pain control protocol while 
assessing outcomes.  
The study  subjects  will be assigned  to the defined  pre-op MMA  regimen  with standard  post- 
op oxycodone based pain control regimen given on an as needed basis. The treatment 
group outcomes will be compared to patients outside of the study including a historica l 
control group (receiving only post -op pain regimen) prior to the implementation of the new 
regimen.  
The studied  treatment  group  will receive  within  3 hours  before  surgery  an oral MMA 
regimen consisting of:  
 
Acetaminophen  975 mg 
Celecoxib  200 mg 
Gabapentin  300 mg 
Oxycodone  10 mg Extended  Release  
 
Pain  control  post-op will be assessed  by RN noted  VAS  pain scale  scores  in PACU. 
Furthermore, opioid sparing and rescue time as determined by the time interval from 
patient  extubation  to time when  pain  medication  is first demanded  in PACU1. In addition, 
variables and secondary outcomes noted in Aims 1 -4 will be measured.  
The potential to selection and recall bias will be significantly reduced by standardizing all 
patients to the new protocol. Additi onally, patients recruited from multiple spine surgeons 
in a private practice model at a community hospital will recruit a wide range of patients 
with variety of pathologies and demographics. A measurement bias may be indicated 
depending on the RN verbally  assessing pain, however utilizing a validated outcome 
measure  such  as the VAS  pain scale  would  minimize  this.  
 
 
5.1.1  Study  Date  Range  and Duration  
 
The study  will be conducted  and continue  from  2020  to 2022.  
 
 
5.1.2  Number  of Study  Sites  
 
The study  will be conducted  out of NYU  Winthrop  hospital  as well as in the outpatient  office 
settings.  
Protocol Number  May 12, 2020 - version 2 
19  
 5.2 Outcome  Variables  
 
5.2.1  Primary  Outcome  Variables  
 
Data  will be collected  using  review  of EPIC  care  electronic  medical  record  (EMR)  with 
notation  of VAS  score  in RN documentation  in PACU  as well as EMR  record  of time of opioid 
administration if requested. The pre -op history and physical will be utilized for extracting 
demographic and clinical data. Finally, long term data will be requested from outpatient 
office  patient  records  at defined  time intervals.  Pain  medication  usage  will be reviewed  with 
prescriptions  given  / noted  in state  (ISTOP)  registries.  Complication  rates  will be assessed 
using  outpatient  records  as well as readmission/ER  documentation  in EMR.  
Measurement  reliability  is dependent  on accuracy  of data  reported  in EMR  and by patients 
in follow up visits. The use of standardized data collection procedures will limit any 
measurement bias that may be observed. Discretionary data outside the standardized 
collection criteria will not be collected. Potential confounders and effect modifiers are 
outlined in the study aims as the patient and treatment characteristics. Their influence will 
be statistically evaluated using stratified univariate and multivariate analyses.  
 
 
5.2.2  Secondary  and Exploratory  Outcome  Variables  
 
5.3 Study  Population  
 
All genders and races will be included in the study. Children will be excluded based on 
differences  in physiology  and small  sample  size that would  influence  the outcome  measures 
and therefore would skew the comparison of interest in the study.  
 
 
5.3.1  Number  of Participants  
 
All patients undergoing elective spine surgery at NYU Winthrop hospital will be screened 
and assessed for potential inclusion into the study. Patients mee ting the inclusion criteria 
and avoiding the exclusion criteria will be recruited into the study. Based on the power 
analysis atleast 31 patients would be needed for the primary outcome. However, in the 
recruitment  period,  the goal would  be to include  as many participants  as possible  (100 -200) 
in order for the secondary and ancillary outcomes to be achieved for statistical subgroup 
analyses.  
 
 
5.3.2  Eligibility  Criteria/Vulnerable  Populations  
Eligibility  Criteria  will be assessed  by the PI as well as the lead author  on the study. 
Inclusion Criteria:  
Protocol Number  May 12, 2020 - version 2 
20  
 Undergoing elective spine surgery at NYU Winthrop 
Age over 18 years  
 
Exclusion  Criteria:  
 
History of neuromuscular disorders 
History of inflammatory arthropathies  
History  of spine  metastases  or active cancer  in spine  
Medical History including any of the following: renal dysfunction, gastric ulcers, hepatic 
dysfunction,  coagulopathic/bleeding  disorders,  prior  adverse  or allergic  reactions  to any 
of the medications in the study  
Age less than  18 years  
Protocol Number  May 12, 2020 - version 2 
21  
 6 - Methods  
6.1 Treatment  - Drug  
 
6.1.1  Identity  of Investigational  Product/New  Drug  
 
All drugs  utilized  are well established  and FDA  approved.  They  are also currently  in 
common use.  
 
Acetaminophen (Tylenol) 
Celecoxib (Celebrex) 
Gabapentin (Neurontin)  
Oxycodone  10 mg Extended  Release  (Oxycontin)  
 
 
6.1.2  Dosage,  Admin,  Schedule  
 
The studied  treatment  group  will receive  within  3 hours  before  surgery  an oral MMA 
regimen consisting of:  
 
Acetaminophen  975 mg 
Celecoxib  200 mg 
Gabapentin  300 mg 
Oxycodone  10 mg Extended  Release  
 
 
6.1.3  Method  of Assignment/Randomization  
 
6.1.4  Blinding  and Procedures  for Unblinding  
 
6.1.5  Packaging/Labelling  
 
Included  in hospital  inpatient  pharmacy.  Administration  through  nursing  similar  to all drugs 
in the inpatient setting. No special packaging or labelling will be utilized.  
 
 
6.1.6  Storage  Conditions  
 
Stored  by hospital  pharmacy  under  appropriate  conditions.  
Protocol Number  May 12, 2020 - version 2 
22  
 6.1.7  Concomitant  therapy  
 
No restrictions  to concomitant  therapy  outside  of allowances  of maximum  medication  doses 
and adverse effects. Concomitant use will be monitored.  
 
 
6.1.8  Restrictions  
 
No restrictions  of note.  
 
 
6.2 Assessments  
 
Pain  control  post-op will be assessed  by RN noted  VAS  pain scale  scores  in PACU. 
Furthermore, opioid sparing and rescue time as determined by the time interval from 
patient  extubation  to time when  pain  medication  is first demanded  in PACU1. In addition, 
variables and secondary outcomes noted in Aims 1 -4 will be measured.  
Data  will be collected  using  review  of EPIC  care electronic  medical  record  (EMR)  with 
notation  of VAS  score  in RN documentation  in PACU  as well as EMR  record  of time of opioid 
administration if requested. The pre -op history and physical will be utilized for extracting 
demographic and clinical data. Finally, long term data will be requested from outpatient 
office  patient  records  at defined  time intervals.  Pain  medication  usage  will be reviewed  with 
prescriptions  given  / noted  in state  (ISTOP)  registries.  Complication  rates  will be assessed 
using  outpatient  records  as well as readmission/ER  documentation  in EMR.  
 
 
 
6.2.1  Efficacy  
 
Measurement  reliability  is dependent  on accuracy  of data  reported  in EMR  and by patients 
in follow up visits. The use of standardized data collection procedures will limit any 
measurement bias that may be observed. Discretionary data outside the standardized 
collection criteria will not be collected. Potential confounders and effect modifiers are 
outlined in the study aims as the patient and treatment characteristics. Their influence will 
be statistically evaluated using stratified univariate and multivariate analyses.  
The study  outcomes  of VAS  pain score  and opioid  sparing/rescue  time will be calculated  as 
a mean  using  PACU  VAS  pain  scores  noted  in EMR  and time from  extubation  to when  opioid 
demanded  in PACU  for pain.  Comparison  to detect  a statistical  difference  of these  outcomes 
compared to historical control group will be done using student's t test. Furthermore,  
patient and treatment characteristics will be evalua ted using univariate and multivariate 
analyses  with cox proportional  hazards  regression  modeling.  Atypical  associations  or unmet 
assumptions will be handled by data transformation to meet assumptions or by the use of 
alternative modeling methods. The sourc e of biostatistical expertise will come from the 
department biostatistician.  
Protocol Number  May 12, 2020 - version 2 
23  
  
6.2.2  Safety/Pregnancy -related  policy  
 
Pregnant  patients  are excluded  from  study.  
 
The risks of the MMA include drug hypersensitivity reactions or adverse effects of the 
medications. In order to minimize these risks a thorough pre -operative history would be 
conducted  and reviewed  to screen  for any known  allergies  as well as any health  conditions 
(ie liver or kidney disease) which would lead to higher risk of adverse effect s of the MMA 
medications.  Furthermore,  since  a single  dose  is use of the medication  it limits  medication 
exposure and risk of adverse effects.  
 
 
6.2.2.1  Adverse  Events  Definition  and Reporting  
 
Adverse events will be defined as any events not considered within the  realm of routine 
post-operative  course.  Adverse  events  will be monitored  in the post-operative  period  while 
in the hospital  as well as once  seen  outpatient  in the office.  Chart  review  from  all providers 
will be screened for adverse events until last follow -up to date.  
 
 
6.2.3  Pharmacokinetics  
 
6.2.4  Biomarkers  
 
6.3 Study  Procedures  
 
Administration of pain medication, including those given in this study are considered 
standard of care. However, the novel use of them in the pre -operative period rather than 
the post-operative period is the question of interest. Furthermore, the use of them in this 
particular regimen is evaluated for efficacy. The outcomes will be assessed from chart 
review  in the immediate  post-operative  period  including  the PACU  and hospital  admission 
course.  Furthermore,  secondary  outcomes  will be assessed  as chart  review  from  office  as 
part of outpatient follow -up. 
 
 
6.3.1  Study  Schedule  
 
Patient  visits  in the office  will be based  on standards  of care  and routine  follow -up practices 
without affect from this study.  
Protocol Number  May 12, 2020 - version 2 
24  
 6.3.2  Informed  Consent  
 
Informed  consent  process  will be followed  per NYU  policy.  
 
Informed consent will be received from all patients included in the study. The information 
obtained will be of vital importan ce to the progression of the field and future treatment of 
patients.  Informed  consent  will be obtained  by either  the PI or the sub investigators  listed 
on the study. Informed consent process will be conducted with a thorough discussion of 
risks and benefit s of the study to the patients followed by permission for participation or 
declination. The consent will be obtained either in print or electronically (utilizing ipad 
resource common used for surgical consents). Consent will be obtained either at pre -op 
visit in the office or at check in to the hospital. Privacy will be protected by keeping all 
information in a safe and secure platform. Consent will be documented and recorded 
alongside the remaining patient variables in order to ensure consent is achieved f or all 
participants.  
 
 
6.3.3  Screening  
 
Patient  screening  will be conducted  by primary  researcher  at pre-operative  visits  or on the 
day of surgery.  
 
 
6.3.4  Recruitment,  Enrollment  and Retention  
 
6.3.5  On Study  Visits  
 
No specific  visits  related  to study  
 
 
6.3.6  End of Study  and Follow -up 
 
Patient  follow -up will be reviewed  from  outpatient  records.  
 
 
6.3.7  Removal  of subjects  
 
Since patients will receive routine care after the single administration of MMA pre - 
operatively.  The outcomes  are assessed  purely  from  chart  review  and patie nt reported 
basis.  
 
 
6.4 Statistical  Method  
Protocol Number  May 12, 2020 - version 2 
25  
  
6.4.1  Statistical  Design  
 
Measurement  reliability  is dependent  on accuracy  of data  reported  in EMR  and by patients 
in follow up visits. The use of standardized data collection procedures will limit any 
measurement bias that may be observed. Discretionary data outside the standardized 
collection criteria will not be collected. Potential confounders and effect modifiers are 
outlined in the study aims as the patient and treatment characteristics. Their infl uence will 
be statistically evaluated using stratified univariate and multivariate analyses.  
The study  outcomes  of VAS  pain score  and opioid  sparing/rescue  time will be calculated  as 
a mean  using  PACU  VAS  pain  scores  noted  in EMR  and time from  extubation  to when  opioid 
demanded  in PACU  for pain.  Comparison  to detect  a statistical  difference  of these  outcomes 
compared to historical control group will be done using student's t test. Furthermore,  
patient and treatment characteristics will be evalua ted using univariate and multivariate 
analyses  with cox proportional  hazards  regression  modeling.  Atypical  associations  or unmet 
assumptions will be handled by data transformation to meet assumptions or by the use of 
alternative modeling methods. The sourc e of biostatistical expertise will come from the 
department biostatistician.  
 
 
6.4.2  Sample  Size  Considerations  
 
At a significance  level  of 5%, in order  to achieve  80%  power  for detecting  a 1 point  mean 
difference  in VAS  pain scores [1], we would  need  a sample  of 31 patients  to assess  the 
primary outcome. Adjusting by approximately 5% to account for patients that are found 
ineligible retrospectively, the total sample size required is 33 patients. Furthermore, 
additional analyses to fulfill Aims 1 -4 would require a larger sample size and would 
constitute separate studies based on final sample size achieved.  
 
[1] Using  the reported  control  group  VAS  scores  by Garcia  et al.8 of 8.4 and standard 
deviation of 2  
 
 
6.4.3  Planned  Analyses  
 
6.4.3.1  Primary  Analyses  
 
6.4.3.2  Secondary  Objectives  Analyses  
 
6.4.3.3  Safety/Pregnancy -related  policy  
Protocol Number  May 12, 2020 - version 2 
26  
 6.4.3.4  Analysis  of Subject  Characteristics  
 
6.4.3.5  Interim  Analysis  
 
6.4.3.6  Health  economic  evaluation  
 
6.4.3.7  Other  
 
6.4.4  Subsets  and Covariates  
 
see aims  and statistical  design.  
 
 
6.4.5  Handling  of Missing  Data  
 
Given the acute and short term nature of study's primary outcome. Missing data is 
expected  to be minimal.  However,  if data  is missing  then  statistically  valid  analyses  under 
the primary missing -data assumptions would be conducted to account for it.  
Protocol Number  May 12, 2020 - version 2 
27  
 7 - Trial  Administration  
7.1 Ethical Considerations: Informed Consent/Assent and HIPAA 
Authorization  
 
In addition to IRB approval and guidelines, all patient data will be kept protected under 
HIPAA guidelines. Informed consent will be obtained from a ll patients. Patients will be 
treated  in a professional  manner  consistent  with standard  of care.  All data  will be handled 
in a secure and professional manner. No financial or other incentives will be provided to 
participants.  
 
 
7.2 Institutional  Review  Board  (IRB)  Review  
 
7.3 Subject  Confidentiality  
 
7.4 Deviations/Unanticipated  Problems  
 
7.5 Data  Collection  
 
Data  will be collected  using  review  of EPIC  care  electronic  medical  record  (EMR)  with 
notation  of VAS  score  in RN documentation  in PACU  as well as EMR  record  of time of opioid 
administration if requested. The pre -op history and physical will be utilized for extracting 
demographic and clinical data. Finally, long term data will be requested from outpatient 
office  patient  records  at defined  time intervals.  Pain  medication  usage  will be reviewed  with 
prescriptions  given  / noted  in state  (ISTOP)  registries.  Complication  rates  will be assessed 
using  outpatient  records  as well as readmission/ER  documentation  in EMR.  
 
 
 
7.6 Data  Quality  Assurance  
 
Measurement  reliability  is dependent  on accuracy  of data  reported  in EMR  and by patients 
in follow up visits. The use of standardized data collection procedures will limit any 
measurement bias that may be observed. Discretionary data outside the standardized 
collection criteria will not be collected. Potential confounders and effect modifiers are 
outlined in the study aim s as the patient and treatment characteristics. Their influence will 
be statistically evaluated using stratified univariate and multivariate analyses.  
 
 
7.7 Study  Records  
Protocol Number  May 12, 2020 - version 2 
28  
 7.8 Access  to Source  
 
7.9 Data  or Specimen  Storage/Security  
 
Data  will be stored  in a password -protected  Microsoft  Excel  file stored  on NYU  network 
drive.  
 
 
7.10  Retention of Records  
 
Records  will be retained  until 1 year  from  the conclusion  of the study.  
 
 
7.11  Study  Monitoring  
 
7.12  Data  Safety  Monitoring  Plan  
 
Primary  oversight  of the study  will be done  by the PI to ensure  proper  evaluation,  following, 
and reporting of AEs from study participants. Secondary monitoring will be done by each 
sub investigator on the review. Furthermore, systematic periodic review of data and AEs 
will be don e on a monthly basis. The accumulated data will include patient pain variables 
collected in the hospital, patient clinical information in EMR, and patient follow -up data.  
Adverse events will be noted and recorded at follow -up visits and include any describ ed 
(see drug package inserts) or undescribed events noted by patients considered by the 
clinician to be outside the realm of normal postoperative care and or recovery. These 
events  will be reported  to the IRB as soon  as possible  or at the monthly  review.  The study 
will be stopped if any unexpected or adverse events not previously reported for the MMA 
are noted.  A summary  of AEs,  deviations,  and report  of the outcomes  of these  data  safety 
monitoring  reviews  will be submitted  to the IRB annually  with the Continuation  Submission  
 
 
7.13  Study  Modification  
 
7.14  Study  Discontinuation  
 
7.15  Study  Completion  
 
7.16  Conflict  of Interest  Policy  
 
7.17  Funding  Source  
Protocol Number  May 12, 2020 - version 2 
29  
 N/A 
 
 
7.18  Publication  Plan  
 
The PI and lead investigator  will hold responsibility  for publication  of data.  Authorship  will 
be given based on significant contributions in the project and writing process.  
Protocol Number  May 12, 2020 - version 2 
30  
 Appendices  
 
Appendix  # Title  Section  Topic  
1 Acetaminophen 
Package Insert  6 Methods  6.1.5  Packaging/L 
abelling  
2 Gabapentin 
Package  Insert  6 Methods  6.1.5  Packaging/L 
abelling  
3 Oxycodone 
Package  Insert  6 Methods  6.1.5  Packaging/L 
abelling  
4 Celecoxib 
Package  Insert  6 Methods  6.1.5  Packaging/L 
abelling  
5 REFERENCES  7 Trial 
Administration  7.18 Publication 
Plan  
Protocol Number  May 12, 2020 - version 2 
31  
  
References  